Amesite
AI documentation and workflow tools for nurses and post-acute care organizations.
Something off on this page? Send us feedback.
Profile
Sells hosted AI subscriptions centered on NurseMagic, which converts nursing inputs into structured documentation and workflow support for practitioners and post-acute organizations. Revenue is primarily subscription-based within a single reportable segment, while the legacy learning platform remains without growth investment.
Sells NurseMagic subscription tools to individual care professionals and post-acute organizations, covering documentation, clinical-information assistance, patient communications, and career tools. Organization users can dictate once, generate structured note drafts, fill fields in existing EMRs, check required elements, and route gaps for clinician review. Pricing scales by active clinician, site, or patient census.
Expands this healthcare focus with an AI-native NurseMagic EMR intended to coexist with or replace legacy systems, while LynkMagic is marketed to fiscal intermediaries, senior-living owners, and enterprise workforce uses. The legacy Amesite Engage learning platform still serves its installed base but receives no growth investment. Revenue comes mainly from hosted-solution subscriptions, and adoption depends on security, regulatory alignment, and integration with care workflows.
Company facts
Key statistics
Year to date −47.5% · Average volume (30d) 108.1K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| May 18, 2026Q3 FY26 | −$0.96 | −$0.15 | +84.4% | $250.0K | $83.3K | −66.7% | +120.07% |
| Feb 5, 2026Q2 FY26 | −$0.96 | −$0.16 | +83.3% | $250.0K | $108.1K | −56.8% | +6.91% |
| Oct 24, 2025Q1 FY26 | — | −$0.14 | — | — | $94.3K | — | +6.27% |
| Sep 29, 2025Q4 FY25 | — | −$0.20 | — | — | $55.8K | — | −4.69% |
Financial highlights
| 12 quarters | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $12.8K | $30.7K | $55.8K | $94.3K | $108.1K | $83.3K | |
| Gross profit | $12.8K | $30.7K | $55.8K | $94.3K | $40.3K | $12.0K | |
| Operating income | −$1.1M | −$687.7K | −$857.7K | −$662.1K | −$745.3K | −$684.1K | |
| Net income | −$1.1M | −$663.4K | −$924.0K | −$642.3K | −$732.5K | −$678.1K | |
| Diluted EPS | −$0.40 | −$0.24 | −$0.20 | −$0.14 | −$0.16 | −$0.15 | |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 37.3% | 14.4% | |
| Operating margin | -8,862.6% | -2,240.9% | -1,538.2% | -702.2% | -689.7% | -820.9% |
Fiscal years (4-quarter sums)FY21 $674.6K · FY22 $697.0K · FY23 $845.0K · FY24 $166.9K · FY25 $110.5K
Balance sheet, Mar 31, 2026Cash & short-term investments $640.7K · Total debt $0 · Total assets $1.5M · Shareholders' equity $1.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 6.55M · Float —
Float — provider float is below the insider stake.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Ann Marie Sastry · director, officer: CHIEF EXECUTIVE OFFICER | 1.93M | 29.39% | Form 4 | May 18, 2026 |
| George Parmer · director | 567.0K | 8.66% | Form 4 | May 18, 2026 |
| Gilbert S. Omenn · director | 143.7K | 2.19% | Form 4 | Mar 10, 2026 |
| J. Michael Losh · director | 138.2K | 2.11% | Form 4 | Mar 10, 2026 |
| Barbie Brewer · director | 136.0K | 2.08% | Form 4 | Mar 10, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 28, 2026 | George Parmer | director | +731,706 | $1.44 |
| Apr 28, 2026 | Ann Marie Sastry | director, officer: CHIEF EXECUTIVE OFFICER | +522,648 | $1.44 |
Peers
- ResMed
Post-acute EHR, documentation, and workflow software via MatrixCare.
- Microsoft
AI nursing documentation and EHR-integrated ambient workflows.
- Oracle
Enterprise EHR platform with embedded AI for clinician workflows.
